SCYNEXIS to Participate in Upcoming January Investor Conferences

Jan 6, 2022

SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million

Dec 22, 2021

BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients

Dec 20, 2021

European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis

Dec 15, 2021

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Dec 6, 2021

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2021

SCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million

Dec 3, 2021

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category

Dec 1, 2021

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

Nov 29, 2021

SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection

Nov 23, 2021